# 267 ‒ The latest in cancer therapeutics, diagnostics, and early detection | Keith Flaherty, M.D.

**Channel:** Peter Attia MD
**Upload Date:** 2023-08-21
**URL:** https://www.youtube.com/watch?v=hBrTtKmcg3k
**Duration:** 125 minutes

## Description

Watch the full episode and view show notes here: https://bit.ly/3YBy1ti
Become a member to receive exclusive content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/

Keith Flaherty is the director of clinical research at the Massachusetts General Hospital Cancer Center and a previous guest on The Drive. In this episode, Keith first delves into the statistics on cancer's prevalence as we age, underscoring the significance of finding effective treatments and early detection methodologies. He touches on the history of cancer therapeutics and illuminates the notable enhancements in cancer therapy within the last decade that are setting the stage for a promising future. He goes into detail on the potential of immunotherapy and therapies that can combat cancer’s evasive tactics while explaining some of the existing challenges around specificity, cost, and scalability. Additionally, Keith highlights the significant leap in early detection methodologies, namely liquid biopsies, which have the potential not only to determine if a cancer is present in an early stage, but also identify the possible tissue of origin.

We discuss:
0:00:00 - Intro
0:00:40 - Keith’s interest and expertise in cancer
0:04:55 - Cancer deaths by decade of life, and how cancer compares to other top causes of death
0:10:33 - The relationship between hormones and cancer
0:18:42 - The link between obesity and cancer
0:23:40 - Current state of treatments for metastatic cancer and reasons for the lack of progress over the decades
0:35:19 - The interplay between the immune system and cancer cells
0:44:29 - Different ways cancer can suppress the immune response, and how immunotherapy can combat cancer’s evasive tactics
0:59:30 - Elimination of a substantial portion of cancers through immune cell engineering faces challenges of specificity, cost, and scalability
1:10:15 - Why TIL therapy isn’t always effective, and the necessity for multimodal therapy to address various aspects of the cancer microenvironment
1:31:49 - The challenge of treating metastatic cancer underscores the importance of early detection to improve survivability
1:38:36 - Liquid biopsies for early detection of cancer and determining the possible tissue of origin
1:49:21 - Commercially available cancer screening tests
1:57:21 - How to address the disparity in cancer care, and the exciting pace of progress for cancer detection and treatment

--------
About:

The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 70 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more.

Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan and simultaneously improving their healthspan. 

Learn more: https://peterattiamd.com

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle

Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies. For a full list of our registered and unregistered trademarks, trade names, and service marks, please review our Terms of Use: https://peterattiamd.com/terms-of-use/

## AI Summary

Here's a comprehensive analysis of the episode:

1. **Executive Summary**:
This episode features Dr. Keith Flaherty discussing the latest advances in cancer therapeutics, diagnostics, and early detection. The conversation focuses heavily on immunotherapy, early detection methods, and the convergence of diagnostic and therapeutic approaches. Key themes include the role of the immune system in cancer treatment, the importance of early detection, and how new technologies are revolutionizing cancer care. [00:00:00]

2. **Key Medical/Scientific Points**:
- 80% of epithelial tumors have novel neoantigens [01:48:05]
- PD1 antibody-based immunotherapy accounts for half of recent advances in cancer treatment [01:30:33]
- Cancer survival rates vary significantly between stage 3 and stage 4, even with identical treatments [01:34:52]
- Circulating tumor DNA can be detected at increasingly sensitive levels [01:51:15]

3. **Health Optimization Tips**:

Universal Recommendations:
- Get recommended cancer screenings (mammography, colonoscopy) [01:39:55]
- Consider multiple screening methods rather than relying on single tests [01:42:23]

Context-specific recommendations:
- High-risk populations should consider serial blood-based testing [01:52:30]
- Work with physicians who understand how to manage positive screening results [01:51:15]

4. **Supplements & Medications**:
- PD1 inhibitors (e.g., Keytruda) discussed as major advancement [01:30:33]
- Checkpoint inhibitors mentioned as important class of drugs [00:57:21]

5. **Biomarkers & Testing**:
- Circulating tumor DNA testing [01:44:11]
- PSA testing discussed with limitations [01:40:26]
- Multiple screening methods recommended for better accuracy [01:42:23]

6. **Notable Quotes**:
"All of these advances are converging in a way that if we keep talking at four-year increments, the pace of progress is going to be substantially greater per unit time" [02:04:49]

7. **Follow-up Questions**:
1. How will AI integration improve cancer diagnosis and treatment selection?
2. What role will metabolic therapies play in future cancer treatment?
3. How can early detection methods be made more accessible to the general population?

Would you like me to expand on any of these sections or provide additional details from other categories?
